Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015 by Tabesh, Maryam et al.
Research: Epidemiology
Cardiovascular disease management in people with
diabetes outside North America and Western Europe in
2006 and 2015
M. Tabesh1,2 , D. J. Magliano1,2, S. K. Tanamas1, F. Surmont4, S. Bahendeka5, C.-E. Chiang6,
J. F. Elgart7, J. J. Gagliardino7, S. Kalra8 , S. Krishnamoorthy9, A. Luk10 , H. Maegawa11,
A. A. Motala12, F. Pirie12, A. Ramachandran9, K. Tayeb13, O. Vikulova14, J. Wong3 and
J. E. Shaw1,2
1Baker Heart and Diabetes Institute, 2Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University,
Melbourne, 3Royal Prince Alfred Hospital Diabetes Centre and the University of Sydney, Sydney, Australia, 4AstraZeneca, London, UK, 5MKPGMS-Uganda Martyrs
University & St. Francis Hospital Nsambya, Kampala, Uganda, 6General Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan, 7CENEXA.
Centro de Endocrinologıa Experimental y Aplicada (UNLP-CONICET), La Plata, Argentina, 8Bharti Research Institute of Diabetes & Endocrinology, Bharti Hospital,
Karnal, Haryana,9Dr A Ramachandran’s Diabetes Hospitals, Chennai, India, 10Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong
SAR, China, 11Shiga University of Medical Science, Shiga, Japan, 12Department of Diabetes and Endocrinology, University of KwaZulu Natal, Durban, South Africa,
13Diabetes Center at AlNoor Specialist Hospital, Makkah, Saudi Arabia and 14FGBU ‘Endocrinology Research Center’, Ministry of Health, Moscow, Russia
Accepted 2 November 2018
Abstract
Aim Optimal treatment of cardiovascular disease is essential to decrease mortality among people with diabetes, but
information is limited on how actual treatment relates to guidelines. We analysed changes in therapeutic approaches to
anti-hypertensive and lipid-lowering medications in people with Type 2 diabetes from 2006 and 2015.
Methods Summary data from clinical services in seven countries outside North America and Western Europe were
collected for 39 684 people. Each site summarized individual-level data from outpatient medical records for 2006 and
2015. Data included: demographic information, blood pressure (BP), total cholesterol levels and percentage of people
taking statins, anti-hypertensive medication (angiotensin-converting enzyme inhibitors, calcium channel blockers,
angiotensin II receptor blockers, thiazide diuretics) and antiplatelet drugs.
Results From 2006 to 2015, mean cholesterol levels decreased in six of eight sites (range: 0.5 to 0.2), whereas the
proportion with BP levels > 140/90 mmHg increased in seven of eight sites. Decreases in cholesterol paralleled increases in
statin use (range: 3.1 to 47.0 percentage points). Overall, utilization of anti-hypertensive medication did not
change. However, there was an increase in the use of angiotensin II receptor blockers and a decrease in angiotensin-
converting enzyme inhibitors. The percentage of individuals receiving calcium channel blockers and aspirin remained
unchanged.
Conclusions Our findings indicate that control of cholesterol levels improved and coincided with increased use of
statins. The percentage of people with BP > 140/90 mmHg was higher in 2015 than in 2006. Hypertension treatment
shifted from using angiotensin-converting enzyme inhibitors to angiotensin II receptor blockers. Despite the potentially
greater tolerability of angiotensin II receptor blockers, there was no associated improvement in BP levels.
Diabet. Med. 00: 1–10 (2018)
Introduction
Cardiovascular disease (CVD) is the leading cause of
mortality and morbidity among people with diabetes, and
is the main contributor to health costs related to diabetes
[1,2]. Numerous randomized clinical trials have
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demonstrated the benefits of blood pressure (BP) and
dyslipidaemia treatment in preventing or delaying the com-
plications of diabetes, including CVD. Management of CVD
has therefore been emphasized as an indispensable part of
diabetes treatment by most guidelines [1–7].
There are several reports on cardiovascular risk manage-
ment in people with diabetes from North America and
Western Europe [8,9]. The National Health and Nutrition
Examination Surveys (NHANES) demonstrated a decline in
the prevalence of hypertension from 64% to 37%, and in the
prevalence of high cholesterol levels from 72% to 55%
among adults with diabetes in the USA between 1971 and
2000 [8]. The Health Survey for England (HSE) reported a
linear decline in cholesterol levels parallel to an increase in
the proportion of people with diabetes on lipid-lowering
drugs (2.2% to 47.4%) between 1994 and 2009 [9]. The
HSE also reported a significant decline in both systolic (SBP)
and diastolic blood pressure and an increase in the use of
anti-hypertensive drugs [9].
There is limited information about how hypertension and
dyslipidaemia treatments are actually delivered outside
North American and Western Europe. These data are
important because they show how targets translate into
practice, and how changes in treatment approaches and
targets are reflected in actual practice. Such information will
also provide a basis for establishing interventions to improve
the delivery of diabetes care with a focus on reducing the risk
of CVD in people with diabetes.
Obtaining data on treatment approaches in diabetes
requires access to medical records. However, only electronic
medical records have the potential to allow extraction of the
large amounts of objective data that are needed for such
projects. The availability of such electronic databases has
facilitated reports on diabetes management in North America
and Western Europe. In recent years, use of such record
systems has spread to other parts of the world, allowing for
the development of projects to examine/investigate how
people with diabetes are actually managed, including the
Real World Experience (RWE) project described here.
The RWE project identified a series of data sources around
the world, outside North America and Western Europe.
These electronic data sources captured individual-level
information from all people with diabetes attending specific
clinical services.
Given that there is not enough information on the
treatment of dyslipidaemia and hypertension outside North
America and Western Europe, the aim of this study was to
explore changes in anti-hypertensive, lipid-lowering and
antiplatelet medications, as well as in BP and cholesterol
target achievement in people with diabetes from 2006 and
2015, outside North America and Western Europe.
Methods
Through a series of meetings and personal links, we sought to
identify clinical services outside North America and Western
Europe that were able to produce clinic- or population-wide
reports on the provision of care to people with diabetes. We
identified eight data sources from seven countries (Argentina,
Australia, Hong Kong, India, Japan, Saudi Arabia and South
Africa) that captured individual-level information from all
people with Type 2 diabetes within a given service or jurisdic-
tion. This is a retrospective study, in which we extracted and
summarized data from all individuals with diabetes aged
> 18 years attending each of the eight clinical services.
There were seven specialist care services and one primary
care/specialist care data source. Each site extracted and
summarized data from the medical records of all those
attending outpatients in the years 2006 and 2015, using a
standardized data-reporting form developed for this project to
collect and report data. Data included demographics, disease
history, diabetic complications, BP, cholesterol levels, and
anti-hypertensive, lipid-lowering and antiplatelet medica-
tions. For people who had more than one laboratory result
ormeasurement during the year, the result closest to themiddle
of the year (30 June) was chosen. If there were two results with
the same date, an averagewas taken. If there were two ormore
results with different dates equidistant to the middle of the
year, the valuewas chosen depending on the quarter inwhich it
fell, in the order: second, third, fourth or first quarter.
The percentage of people who reached BP targets of ≤ 140/
90 and ≤ 130/80 mmHg, and the percentage of people on
anti-hypertensive therapy were reported by each site. Hyper-
tension was defined as BP > 140/90 mmHg or taking anti-
hypertensive medications. To understand how well people
with hypertension were managed, the percentage of those
with BP above target and who were not on anti-hypertensive
medications was also reported. Information was also col-
lected separately for proportions of each class of anti-
What’s new?
• Mean total cholesterol levels in people with diabetes
decreased with a simultaneous increase in statin use.
• The percentage of people with blood pressure (BP)
> 140/90 mmHg increased, which may reflect the
change in BP targets from ≤ 130/80 to ≤ 140/90 mmHg
that occurred between 2006 and 2015.
• Anti-hypertensive treatment approaches shifted
towards using more angiotensin II receptor blockers
with a simultaneous decline in the use of angiotensin-
converting enzyme inhibitors.
• Although improved control of high cholesterol in
people with diabetes was encouraging, further efforts
are required to improve hypertension management in
people with diabetes.
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hypertensive medication including angiotensin-converting
enzyme (ACE) inhibitors, angiotensin II receptor blockers
(ARBs), thiazide diuretics and calcium channel blockers. The
proportions of people using statins and antiplatelet medica-
tions were also reported by each site.
Analyses were conducted using Stata (v. 14; Stata Corp,
College Station, TX, USA). We reported continuous variables
as mean  standard deviation (SD) and categorical variables
as proportions. Differences in the general characteristics of
the study population between 2006 and 2015, were assessed
using the Student’s t-test for means and the z-test for
proportions, as appropriate. For all analyses, a P-value
< 0.05 was considered statistically significant.
Because this was an analysis of data already collected for
clinical purposes, and no individual-level data left any
clinical sites, no consent was obtained from the study
population, and some sites did not require local ethics
approval. The study was approved by the Monash University
Human Research Ethics Committee (number 1441), and the
Alfred Ethics Committee (number 64/15) in Australia and in
some of the sites, as required by local guidelines.
Results
Study population
For the purpose of this analysis, the RWE study includes
39 684 people with diabetes from eight clinical sites in seven
different countries (Table 1). All those in the study popula-
tion received specialist care services, except in Argentina
where 26% and 74% were treated in primary care in 2006
and 2015, respectively. There was heterogeneity in the
characteristics of the study population between sites. Sample
size varied from 291 in Japan to 13 348 in India. The mean
age of the population with diabetes ranged from 46 to
73 years. Table 2 shows that from 2006 to 2015, the mean
age of the population decreased significantly in Argentina,
India and South Africa, increased significantly in Hong Kong,
Saudi Arabia and Japan, and remained unchanged in
Australia. BMI increased significantly by 1 kg/m2 in Argen-
tina and by 0.5 kg/m2 in India, and decreased significantly by
0.5 kg/m2 in Australia (Sydney), Hong Kong and Japan. The
change in mean BMI was not significant at other sites.
Table 1 Characteristics of people with Type 2 diabetes in 2006 and 2015 stratified by clinical service
HbA1c
Country (centre) Year N Male* Age (years) mmol/mol % BMI (kg/m2)
Duration of
diabetes (years)
Argentina (Centro de Endocrinologıa Experimental y Aplicada)
2006 2 146 48.4 (1039) 58.1 (11.1) 61 7.7 (1.8) 30.1 (5.4) 9.3 (9.0)
2015 1 828 49.6 (907) 54.7 (9.9) 63 7.9 (2.1) 32.1 (6.4) 8.9 (7.2)
P-value < 0.001 < 0.001 < 0.001 0.06
Australia (Baker Heart and Diabetes Institute, Melbourne)
2006 4 080 57.2 (2331) 61.7 (15.6) 60 7.6 (1.4) 29.8 (6.0) 9.8 (9.8)
2015 4 059 60.6 (2459) 61.8 (15.7) 61 7.7 (1.4) 29.7 (5.8) 13.8 (10.4)
P-value 0.38 < 0.001 0.22 P< 0.001
Australia (Royal Prince Alfred Hospital, Sydney)
2006 1 406 58.2 (818) 60.3 (13.6) 58 7.5 (1.5) 30.7 (6.3) 11.2 (8.4)
2015 1 351 59.5 (804) 59.6 (15.3) 64 8.0 (1.7) 30.2 (6.4) 14.2 (10.2)
P-value 0.1 < 0.001 0.01 P< 0.001
Hong Kong (Prince of Wales Hospital)
2006 788 49.2 (388) 58.5 (12.9) 57 7.4 (1.6) 25.7 (4.3) 6.6 (7.1)
2015 2 043 54.2 (1108) 59.9 (12.0) 60 7.6 (1.4) 26.2 (4.8) 11.3 (8.8)
P-value 0.003 < 0.001 0.005 P< 0.001
India (Dr. A Ramachandran’s Diabetes Hospitals)
2006 6 022 58.4 (3516) 58.0 (12.0) 88 8.4 (1.8) 26.9 (4.5) 13.7 (9.3)
2015 13 348 59.5 (7945) 54.0 (13.0) 85 8.1 (1.7) 27.5 (4.8) 11.5 (9.3)
P-value < 0.001 < 0.001 P< 0.001 P< 0.001
Japan (Shiga University of Medical Science)
2006 384 53.9 (207) 63.0 (11.0) 61 7.7 (1.1) 24.0 (3.8) 18.0 (10.0)
2015 291 59.8 (174) 73.0 (5.0) 55 7.2 (1.0) 23.5 (3.5) 17.0 (11.0)
P-value < 0.001 < 0.001 0.04 0.1
Saudi Arabia (Diabetes Center at AlNoor Specialist Hospital)
2006 383 41.5 (159) 53.5 (16.8) 60 7.6 (2.1) 31.3 (5.6) 8.9 (7.7)
2015 276 51.4 (142) 56.4 (12.1) 68 8.4 (1.8) 31.7 (6.7) 9.6 (8.8)
P-value 0.007 < 0.001 0.202 0.139
South Africa (Inkosi Albert Luthuli Central Hospital)
2006 601 34.6 (208) 49.3 (17.5) 83 9.7 (2.5) 30.2 (7.3) 13.2 (11.0)
2015 681 36.4 (248) 46.5 (20.4) 75 9.0 (2.3) 29.9 (7.5) 14.0 (10.3)
P-value 0.004 < 0.001 0.23 0.08
Values are given as mean (SD) except * n (%).
P-values were calculated using the Student’s t-test for means and z-test for proportions comparing the values in 2006 and 2015.
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Duration of diabetes decreased significantly in India,
increased in Australia and Hong Kong, and remained
unchanged at other sites. Mean HbA1c increased significantly
in Argentina (by 0.2 percentage points), Australia (Mel-
bourne) (0.1 percentage points) Australia (Sydney) (0.5
percentage points), Hong Kong (0.2 percentage points) and
Saudi Arabia (0.8 percentage points), and decreased signifi-
cantly in Japan (0.5 percentage points) and South Africa (0.7
percentage points).
Management of dyslipidaemia
There was a decline in mean cholesterol level among people
with diabetes in seven of the eight clinical sites (range: 0.5
to 0.2 mmol/mol) and an increase in Australia
(Melbourne), from 2006 to 2015 (Fig. 1a). This improve-
ment was accompanied by a large increase in statin use
during the study period (range: 3.1 to 47 percentage points)
(Fig. 1b). However, the magnitude of the reduction in mean
cholesterol levels differed by site (Fig. 1a). Argentina,
Japan, Saudi Arabia and South Africa showed the highest
proportion of people with high cholesterol in 2006 and
2015. The greatest reductions in mean cholesterol levels
were observed mainly at those sites with the highest mean
cholesterol levels in 2006 (Argentina, Hong Kong, Japan,
Saudi Arabia and South Africa). At each site, at least half of
the population with diabetes was on statin therapy in 2015
(Table 2).
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FIGURE 1 (a) Mean total cholesterol in 2006 and 2015, and change (mmol/l) from 2006 to 2015. (b) Prevalence of statin use in 2006 and 2015, and
percentage point change from 2006 to 2015. AR, Argentina; AU_M, Australia, Melbourne; AU_S, Australia, Sydney; HK, Hong Kong; SA, Saudi
Arabia; IN, India; JP, Japan; ZA, South Africa
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Management of hypertension
In 2015, South Africa and Japan had the highest prevalence
of hypertension, defined as BP ≥ 140/90 mmHg or taking
anti-hypertensive medication (Table 2). There was an
increase in the proportion of people with BP ≥ 140/
90 mmHg (1.4–21.3 percentage points) at all sites except
Australia (Sydney) where there was a 13.8 percentage point
reduction in people with BP > 140/90 mmHg (Fig. 2a). The
prevalence of anti-hypertensive medication use declined
significantly in Argentina, Australia and South Africa
(range: 13.1 to 7.3 percentage points), increased signif-
icantly in Hong Kong and India (range 1.8 to 4.3
percentage points), and remained unchanged in Japan and
Saudi Arabia.
Table 2 shows that SBP decreased significantly in Argen-
tina (from 132 to 129 mmHg), Australia (Sydney) (130 to
123 mmHg) and India (132 to 130 mmHg). Mean SBP
increased in Australia (Melbourne) (130 to 133 mmHg),
Japan (132 to 140 mmHg) and Saudi Arabia (127 to
FIGURE 2 (a) Prevalence of patients with BP>140/90 in 2006 and 2015, and percentage point change from 2006 to 2015. (b) Prevalence of
antihypertensive medications use in 2006 and 2015, and percentage point change from 2006 to 2015. AH, anti-hypertensive medications; AR,
Argentina; AU_M, Australia, Melbourne; AU_S, Australia, Sydney; HK, Hong Kong; SA, Saudi Arabia; IN, India; JP, Japan; ZA, South Africa
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134 mmHg), whereas in other clinics, there was no signif-
icant change in mean SBP.
From 2006 to 2015, the prevalence of hypertension,
defined as either anti-hypertensive medication use or a BP
> 140/90 mmHg, decreased significantly in Australia
(Sydney) (11.3 percentage points), Australia (Melbourne)
(2.7 percentage points) and Argentina (4.4 percentage
points), and increased significantly at the other sites (range
3.0 to 11.8 percentage points). The prevalence of untreated
hypertension increased significantly in Argentina (2.3 per-
centage points), Australia (Melbourne) (12.3 percentage
points), Hong Kong (5.5 percentage points), Japan (3
percentage points), Saudi Arabia (16.9 percentage points)
and South Africa (13.2 percentage points), and decreased
significantly in Australia (Sydney) (2 percentage points) and
India (2.8 percentage points). The proportion of people using
each class of anti-hypertensive medication is presented in
Table 3. ACE inhibitors were the most commonly prescribed
anti-hypertensive medication in most sites, followed by
calcium channel blockers and ARBs. Although there was
no increase in the total proportion of people on anti-
hypertensive treatment, there was a change in the type of
medication used. There was a reduction in the proportion of
people taking ACE inhibitors from 2006 to 2015. Simulta-
neously, utilization of ARBs increased. Furthermore, we
observed huge variability in the use of ARBs and ACE
inhibitors between sites. For example, the prescription of
ARBs among people with diabetes varied from 4.0% in
South Africa to 35.0% in Australia (Melbourne) in 2006; this
heterogeneity in ARB usage persisted in 2015, when 14.2%
and 45.0% used ARBs in South Africa and Japan, respec-
tively. Of note, heterogeneity in the use of ACE inhibitors
persisted from 2006 (from 4.7% in India to 56.1% in South
Africa) to 2015 (from 3.2% in India to 60.7% in Argentina).
For other types of medication, such as statin and antiplatelet
agents, we did not observe such heterogeneity in the
prescription rates between sites.
Therewas amixed pattern for use of other anti-hypertensive
medications such as thiazide diuretics and calcium channel
blockers in different sites. Between 2006 and 2015, the
prescription of thiazide diuretics decreased significantly in
South Africa but did not change in other clinical sites.
Utilization of calcium channel blockers decreased significantly
in Australia (Melbourne), India and South Africa, increased
significantly inAustralia (Sydney) andHongKong, and remain
unchanged in other sites. Prescription of aspirin and other
Table 3 Prevalence of use of cardiovascular disease drug classes in people with diabetes in 2006 and in 2015 stratified by site
Country Year N ARB ACEi Thiazides CCB Statins Anti-platelet
Argentina
2006 2 146 8.9 (190) 52.4 (1124) 14.4 (310) 11.7 (252) 30.9 (664) –
2015 1 828 17.3 (317) 60.7 (1109) 16.1 (295) 12.7 (232) 52.0 (951) 35.9 (656)
P-value < 0.001 < 0.001 0.08 0.16 < 0.001 N/A
Australia (Melbourne)
2006 4 080 35.0 (1429) 33.9 (1383) 26.0 (1061) 26.0 (1059) 54.1 (2207) 21.0 (857)
2015 4 059 33.7 (1370) 22.0 (382) 25.7 (1042) 23.1 (937) 61.0 (2477) 30.7 (1247)
P-value 0.11 < 0.001 0.37 < 0.001 < 0.001 < 0.001
Australia (Sydney)
2006 1 406 32.9 (452) 37.9 (522) 16.3 (227) 21.6 (297) 59.0 (153) 38.5 (529)
2015 1 351 38.7 (489) 25.1 (318) N/A 26.1 (330) 71.0 (161) 31.0 (396)
P-value < 0.001 < 0.001 N/A 0.002 < 0.001 < 0.001
Hong Kong
2006 788 5.1 (40) 35.2 (277) N/A 29.7 (234) 23.5 (185) 19.0 (150)
2015 2 043 18.4 (377) 30.8 (629) 3.1 (8.3) 35.4 (724) 54.8 (1119) 23.2 (474)
P-value < 0.001 0.01 N/A 0.002 < 0.001 0.007
India
2006 6 022 19.6 (1077) 4.7 (258) 9.0 (439) 16.8 (925) 24.9 (1371) 18.1 (996)
2015 13 348 27.3 (3649) 3.2 (426) 9.4 (1248) 15.6 (2081) 51.2 (6831) 21.4 (2862)
P-value < 0.001 < 0.001 0.19 0.02 < 0.001 0.09
Japan
2006 384 27.3 (105) 18.8 (72) 14.8 (57) 29.7 (114) 39.8 (153) 33.6 (129)
2015 291 45.0 (131) 7.9 (23) 17.5 (51) 32.6 (95) 55.3 (161) 28.9 (84)
P-value < 0.001 < 0.001 0.17 0.21 < 0.001 0.09
Saudi Arabia
2006 383 5.2 (20) 30.3 (116) 9.4 (36) 14.6 (56) 49.3 (189) 70.8 (271)
2015 276 20.3 (56) 24.6 (68) 8.3 (23) 18.5 (51) 64.1 (177) 59.1 (163)
P-value < 0.001 0.053 0.31 0.09 < 0.001 < 0.001
South Africa
2006 601 4.0 (24) 56.1 (337) 36.4 (219) 47.6 (286) 50.1 (301) 49.1 (295)
2015 681 14.2 (97) 42.3 (288) 22.6 (154) 33.8 (230) 53.2 (362) 37.3 (254)
P-value < 0.001 < 0.001 < 0.001 < 0.001 0.14 < 0.001
Values are presented as n or n (%).
N/A, not available; ARB, angiotensin II receptor blocker; ACE, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker.
P-values were calculated using the z-test for proportions.
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antiplatelet medications: decreased significantly in three sites,
Australia (Sydney), Saudi Arabia and South Africa (range
11.8 to 7.5 percentage points); increased in Australia
(Melbourne) (9.7 percentage points), Hong Kong (4.2 per-
centage points) and India (3.3 percentage points); and
remained unchanged at other clinical sites (Table 3).
Discussion
This study provides information on CVD management in
39 684 people with Type 2 diabetes from seven countries.
Despite the existence of heterogeneity between countries in
terms of cardiovascular risk management, similar changes in
treatment approaches can be observed. In general, mean
cholesterol levels decreased in the study population in line
with increased statin use. In addition, lower cholesterol levels
among those on statins likely reflects the use of higher doses
and more potent statins. The proportion of people on anti-
hypertensive medication decreased slightly or remained
unchanged with concomitant increases in the proportion of
people with BP > 140/90 mmHg in most sites. Anti-
hypertensive treatment patterns shifted from using predom-
inantly ACE inhibitors towards using more ARBs. Never-
theless, the change to newer hypertension drugs was not
associated with improvement in BP levels.
The benefit of statin use both for primary and secondary
prevention of CVD events in people with diabetes is well-
established and extensively investigated [10]. The American
Diabetes Association (ADA) guidelines recommend a lower
LDL-cholesterol target (< 1.8 mmol/l) for people with dia-
betes and a concomitant cardiovascular event than for the
general population (< 2.6 mmo/l) [11]. The results of our
study are consistent with those reported by the HSE, which
showed that from 1994 to 2009, total cholesterol levels
declined in people with diabetes from 6.1 to 4.5 mmol/l, in
parallel with an increase in the prescription of statins from
2.2% to 47.4% [9]. A study of people with diabetes from
Taiwan also showed a threefold increase in statin use in a 7-
year period [12]. Similar to our findings, a study of people
with Type 2 diabetes in the USA showed a substantial
increase in statin use (from 4.2% in 1988 to 51.4% in 2010),
accompanied by substantial improvement in the percentage
of people achieving the LDL-cholesterol target of
< 2.6 mmol/l from 9.9% to 56.2% [13].
Our study shows that nearly 80% of those with BP > 140/
90 mmHg were taking anti-hypertensive medication. Rea-
sons for failing to achieve the BP target despite receiving
treatment for hypertension may include poor adherence
[14,15], inadequate efficacy of anti-hypertensive medica-
tions, side effects of drugs and variability in BP measurement.
BP management in hypertensive individuals with diabetes has
undergone some significant changes over the past decade.
ADA targets for management of hypertension among people
with Type 2 diabetes have changed over time. In 2006, ADA
guidelines recommended a BP target of 130/80 mmHg for
people with diabetes. This was based on several large studies
such as the Hypertension Optimal Treatment study and the
United Kingdom Prospective Diabetes Study, which showed
that maintaining BP levels < 130/80 mmHg reduced cardio-
vascular events in people with diabetes. However, the pooled
analysis of mortality risk associated with the use of intensive
BP targets vs. standard targets in people with Type 2 diabetes
reported no benefit or even harm when the lower BP targets
were achieved [16]. This meta-analysis demonstrated that
although the use of intensive vs. standard BP targets might
cause a small reduction in the risk for stroke, there was no
evidence of benefit from intensive targets in reducing risk of
mortality or myocardial infarction, but rather there was an
increased risk of hypotension and other adverse events [16].
Thus, there has been a modification to recent guidelines
recommending a less stringent BP target, i.e. 140/90 mmHg,
with an emphasis on the individualization of BP management
with regard to age and the existence of other risk factors.
Another explanation for the lack of improvement in BP
control is the variability in BP targets suggested by different
guidelines. ADA guidelines recommend a BP target of < 140/
90 mmHg [17] for people with diabetes, whereas the
American Association of Clinical Endocrinologists/American
College of Endocrinology AACE/ACE [4] and IDF [1]
recommended a BP target of < 130/80 mmHg. In 2015,
national guidelines for Australia and Japan also recom-
mended a BP target of < 130/80 mmHg [18,19]. Despite the
only change in target BP being a move away from 130/
80 mmHg, it is concerning that the percentage of people
with BP > 140/90 mmHg increased at all but one site. This
suggests that raising BP targets from 130/80 to 140/
90 mmHg can have the undesired effect of increasing the
number of people failing to achieve the 140/90 mmHg
target, and this should be considered in future guideline
deliberations.
In this study, ACE inhibitors were the most popular anti-
hypertensive medication at most sites, which is consistent
with most guidelines. Nevertheless, we observed a shift
from prescription of ACE inhibitors to ARBs from 2006 to
2015. According to guidelines [20,21], ACE inhibitors and
ARBs (if intolerant to ACE inhibitors) are the first line of
anti-hypertensive medication for people with diabetes.
Calcium channel blockers, thiazides and thiazide-like
diuretics are recommended as the second line of treatment
when patients fail to reach the target with first-line drugs.
Meta-analyses directly comparing ACE inhibitors and
ARBs found that both had similar effects in reducing
mortality and cardiovascular events [22]. However, ARBs
have a better side effect profile than ACE inhibitors in
regard to cough, which is reported in 44% in those on
ACE inhibitors compared with only 4% for those on
ARBs [23].
One of the reasons for the heterogeneity in prescribing
anti-hypertensive medications between sites is the number of
different classes of anti-hypertensive medications available.
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Thus, health professionals have a range to choose from and
choice is based on the availability, cost, side effects,
tolerability and local guidelines.
The ADA recommended low-dose aspirin for secondary
prevention of cerebrovascular and cardiovascular events
[24], and for primary prevention for those with high risk of
CVD. The high-risk group includes men and women with
diabetes aged ≥ 50 years who have at least one additional
major risk factor (family history of premature atherosclerotic
CVD, hypertension, dyslipidaemia, smoking or albuminuria)
and are not at increased risk of bleeding. In our study, use of
antiplatelet therapy was generally below 50% and the
change between 2006 and 2015 was variable. A recent
population-based study in the USA showed a slight decrease
in the prevalence of aspirin use for both primary and
secondary CVD prevention from 2012 to 2015 [25]. Poten-
tial reasons for the variability in aspirin use in our study
include controversy in recent years regarding the benefit of
aspirin use among those without prior CVD events. Two
studies published in 2008 and 2009, showed no clear benefit
of aspirin use in the primary prevention of CVD events in
people with diabetes. Furthermore, the Antithrombotic
Trialists’ (ATT) collaborators, in an individual patient-level
meta-analysis in 2009, showed some evidence of sex dispar-
ity in that aspirin significantly reduced stroke only in women;
by contrast, aspirin reduced the risk of atherosclerotic CVD
only in men [26].
The strengths of our study include the large sample size
and the non-trial setting that the data represent. Clinical
trials are conducted under strict conditions that do not
necessarily represent real-world situations in which people
with diabetes are managed less rigorously. Although indi-
vidual services are not necessarily representative of the
population within which they are located, they provide
information on all attending individuals, thus removing
volunteer bias. Using data from medical records, our study
observed management in real-world settings. The aggregate
nature of the data we collected is a limitation to our study,
because it prevents the analysis of relationships between
change in medication use, risk factors, and changes in BP and
lipid levels at an individual level. We also cannot claim
causality because the study does not have a longitudinal
design and we used aggregate not individual-level data. Our
study is also limited by the selection of sites, which may not
be representative of diabetes and CVD management in each
country. The countries and clinics that we included do not
adequately represent the most resource-limited settings,
where findings may have been different. The goal of this
study was to explore real-world experience of CVD man-
agement. It is uncertain whether any changes we see in our
eight clinics are similar to those in other clinics in each
country. We believe that this is the first step to understanding
any change at the population level; however, we acknowl-
edge the limitation of this study regarding its generalizability
to the whole population of each country. The number of
clinical services involved in this study is relatively small, and
further research should be performed with population-based
designs and in more locations. Adherence to treatment, as
one of the likely causes of treatment failure, also needs to be
addressed in future studies.
Conclusion
This study showed that from 2006 to 2015, there was
improvement in the management of cholesterol, likely due to
a substantial increase in statin use. The proportion of people
with BP > 140/90 mmHg increased and anti-hypertensive
treatment shifted from ACE inhibitors to ARBs. Such an
increase in the proportion of those with BP > 140/90 mmHg
occurred concomitant to the increase the in BP targets from
130/80 to 140/90 mmHg in international guidelines.
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